Diabetic nephropathy;Dijabetička nefropatija

Medicina Fluminensis

Volumn 46, Issue 4, 2010, Pages 360-375

  Vujičić, Božidar ^a   Turk, Tamara ^a   Crnčević Orlić, Željka ^a   Dordević, Gordana ^b   Rački, Sanjin ^a  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Chronic renal failure; Diabetes; Diabetic nephropathy; Microalbuminuria; RAAS inhibitors

Indexed keywords

EID: 79952429020     PISSN: 18476864     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Reutens AT, Prentice L, Atkins R. The Epidemiology of Diabetic Kidney Disease, In: Ekoe J (ed.) The Epidemiology of Diabetes Mellitus, 2008. John Wiley & Sons Ltd: Chichester. 499-518.
2. Adler AI, Stevens RJ, Manley SE, Bilous WR, Cull AC, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;225-32. (Pubitemid 35463925)
3. Kimmelstiel P, Wilson C. Benign and malignant hypertension and nephrosclerosis. A clinical and pathological study. Am J Pathol 1936;12:45-8.
4. Vrhovac B, Jakšić B, Reiner Ž, Vucelić B (eds). Interna medicina. 4. izd. Zagreb: Naklada Ljevak, 2008;1258-9.
5. Mogensen CE. Microalbuminuria, blood presure and diabetic renal disease: origin and development of ideas. Diabetologia 1999;42:263-85. (Pubitemid 29111432)
6. Buchan IE (ed.) Arcus QuickStat Biomedical version. 1. izd. Cambridge: Addison Wesley Longman Ltd; 1997.
7. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-2. (Pubitemid 12123979)
8. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60. (Pubitemid 14179541)
9. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-24. (Pubitemid 20263324)
10. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001;60:219-27. (Pubitemid 32587557)
11. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I et al. Predictors of the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105-8. (Pubitemid 38608441)
12. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003;26:2392-9. (Pubitemid 36993332)
13. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9. (Pubitemid 19256660)
14. Craig KJ, Donovan K, Munnery M, Owens DR, Williams JD, Phillips AO. Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care 2003;26:1806-11. (Pubitemid 36929124)
15. Nacionalni registar osoba sa šećernom bolešću CroDiab - izvješće za 2009. Available at: http://www.hzjz.hr/ publikacije/crodiabreg2009.pdf Accessed September 23rd, 2010.
16. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME et al. Cellular basis of diabetic nephropathy 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 2002;51:506-13. (Pubitemid 34764810)
17. Solini A, Dalla Vestra M, Saller A, Nosadini R, Crepaldi G, Fioretto P. The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 2002;51:251-5. (Pubitemid 34518007)
18. Rudberg S, Rasmussen LM, Bangstad HJ, Osterby R. Influence of insertion/deletion polymorphism in the ACEI gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23:544-8. (Pubitemid 30185802)
19. Harris RD, Steffes MW, Bilous RW, Sutherland DER, Mauer SM. Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 1991;40:107-14.
20. Olson JL, De Urdaneta AG, Heptinstall RH. Glomerular hyalinosis and its relation to hyperfiltration. Lab Invest 1985;52:387-98. (Pubitemid 15056796)
21. Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G. The nephropathy of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998;9:2336-43. (Pubitemid 28543812)
22. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabets mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol hypertens 2008;17:32-6. (Pubitemid 350295194)
23. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB et al. On behalf of the Renal pathology Society. Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol. In Press 2010.
24. Nasr SH, D'Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 2007;18:2032-6. (Pubitemid 47041068)
25. Olsen S, Mogensen CE. How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 1996;39:1638-45. (Pubitemid 26397381)
26. Galešić K, Sabljar-Matovinović M, Prkačin I, Kovačević- Vojtušek I. Dijabetička nefropatija i primarne bolesti glomerula. Liječ Vjesn 2009;131:141-5.
27. Stadler G, Schmidt R. Severe funcional disorders of glomerular capillaries and renal hemodynamics in treated diabetes mellitus during childhood. Ann Pediatr (Paris) 1959;193:129-38.
28. Mogensen CE. Kidney function and glomerular permeability to macromolecules in early juvenile diabetes. Scand J Clin Lab Invest 1971;28:79-90.
29. Serri O, Beauregard H, Brazeau P, Aribat T, Lambert J, Harris A et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetics. JAMA 1991;265:888-92.
30. Hirschberg R, Brunori G, Kopple JD, Guler, HP. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 1993;43:387-97. (Pubitemid 23162832)
31. Hirschberg R, Kopple JD. The growth hormone-insulinlike growth factor I axis and renal glomerular filtration. J Am Soc Nephrol 1992;2:1417-22.
32. Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensinconverting enzyme inhibition in diabetes. Kidney Int 2005; 68:1722-8. (Pubitemid 43169916)
33. Passariello N, Sepe J, Marrazzo G, De Cicco A, Peluso A, Pisano MC et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 1993;16:789-95. (Pubitemid 23127187)
34. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in rarly type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003;14:530-7. (Pubitemid 36150878)
35. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. J Am Soc Nephrol 1999;10:2569-76.
36. Vlassara H. Protein glycation in the kidney: Role in diabetes and aging. Kidney Int 1996;49:1795-804. (Pubitemid 26188071)
37. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor -mediated renal fibrosis predominately through transforming growth factor beta-independent pathway. Am J Pathol 2004;165:2033-43. (Pubitemid 39578381)
38. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE. Early glycosilation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992;42:875-81.
39. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in mesangial cells cultured in a normal glucos milieu mimics the diabetic phenotype. J Clin Invest 1995;96:1802-14.
40. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, wang FS. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006;17:2812-20. (Pubitemid 44484671)
41. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-9. (Pubitemid 28327814)
42. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006;70:2100-8. (Pubitemid 44871372)
43. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4:444-52.
44. Daneman D, Crompton CH, Balfe JW, Sochett EB, Chatzilias A, Cotter BR et al. Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 1994;46:1154-59. (Pubitemid 24319956)
45. Nguyen G. Renin/prorenin receptors. Kidney Int 2006;69:1503-6.
46. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950-61. (Pubitemid 44036179)
47. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CPM. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006;69:1654-61.
48. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433-42. (Pubitemid 351355386)
49. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003;18:1392-6. (Pubitemid 36826963)
50. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405. (Pubitemid 29353136)
51. Wang S, De Caestecker M, Kopp J, Mitu G, LaPage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17:2504-12. (Pubitemid 44300966)
52. Turk T, Leeuwis JW, Gray J, Torti SV, Lyons KM, Nguyen TQ et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 2009;57:623-31.
53. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthöfer H, Zaoui P et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-6. (Pubitemid 35352051)
54. Tap RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004;44:792-8. (Pubitemid 39445910)
55. Satko SG, Langefeld CD, Daeihagh P, Bowden DB, Rich SS, Freedman BI. Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. Am J Kidney Dis 2002;40:489-94. (Pubitemid 34971276)
56. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA 1992;268:3079-84.
57. Svensson M, Nystrom L, Schon S, Dahlquist G. Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population- based study. Diabetes Care 2006;29:538-42. (Pubitemid 44115350)
58. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40. (Pubitemid 47362321)
59. Randeree HA, Omar HA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992;15:1258-63.
60. Nosadini R, Sambataro M, Thomaseth K, Pacini G, Cipollina MR, Brocco E et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int 1993;44: 139-46. (Pubitemid 23198037)
61. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085-90. (Pubitemid 35192814)
62. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006;296:421-6. (Pubitemid 44127526)
63. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991;324:1626-32.
64. Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, Owens DR et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992;41:829-35.
65. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993;3:1458-66.
66. Earle K, Viberti GC. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 1994;45:434-7. (Pubitemid 24065077)
67. Hayashi K, Epstein M, Loutzenheiser R, Forster H. Impaired myogenic responsiveness of afferent arteriole in streptozotocin-induced diabetic rats: Role of eicosanoid derangements. J Am Soc Nephrol 1992;2:1578-86.
68. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008;168:2440-7.
69. Krolewski M, Eggers PW, Warram JH. Magnitude of end stage renal disease in IDDM: A 35 year follow-up study. Kidney Int 1996;50:2041.
70. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005;29:1115-20. (Pubitemid 41192220)
71. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003;26:911-6 (Pubitemid 36929364)
72. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005;28:1988-94. (Pubitemid 41060974)
73. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994;43:441-6. (Pubitemid 24064253)
74. Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992;41:758-62.
75. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000;58: 1719-31.
76. Huang F, Yang Q, Chen L, Tang S, Liu W, Yu X. Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. Clin Nephrol 2007;67:293-7.
77. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D. Renal pathology patterns in type II diabetes mellitus: Relationship with retinopathy. Nephrol Dial Transplant 1998;13:2547-52. (Pubitemid 28445867)
78. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12.
79. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortalityin type 1 diabetic nephropathy. Diabetes Care 2008;31:1177-82.
80. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parvinh HH, Goldschmeding R et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006;29:83-8 (Pubitemid 44033436)
81. Pfeiffer A, Middelberg-Bisping K, Drewes C, Shatz H. Elevated plasma levels of transforming growth factorbeta 1 in NIDDM. Diabetes Care 1996;19:1113-7. (Pubitemid 26334260)
82. Heine GH, Sester U, Girndt M, Kohler H. Acanthocytes in the urine: useful tool to differentiate diabetic nephropathy from glomerulonephritis? Diabetes Care 2004;27:190-4. (Pubitemid 38196731)
83. Myers DI, Poole LJ, Imam K, Scheel PJ, Eustace JA. Renal artery stenosis by three-dimensional magnetic resonance angiography in type 2 diabetics with uncontrolled hypertension and chronic renal insufficiency: Prevalence and effect on renal function. Am J Kidney Dis 2003;41:351-9. (Pubitemid 36152453)
84. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67.
85. Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006;69:907-12.
86. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006;7:3-14. (Pubitemid 43891239)
87. Berl T, Hunsicker LG, Lewis JB, Pffefer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005;16:2170-79. (Pubitemid 41716450)
88. European Society of Hypertension. Guidelines for the Management of Arterial Hypertension. Journal of Hypertension 2007;25:1105-87.
89. Cooper ME. The role of the renin-angiotenzin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17:16S-20S. (Pubitemid 39469911)
90. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:1100-8. (Pubitemid 34274109)
91. Reudelhuber TL. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005;46:1261-2. (Pubitemid 43189720)
92. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-4. (Pubitemid 8073845)
93. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30. (Pubitemid 16062649)
94. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney disease: evolving targets in renoprotection. Nat Rev Drug Discov 2008;7:936-53.
95. Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani A et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33. (Pubitemid 41773378)
96. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80. (Pubitemid 36513336)
97. Estacio RO. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors. Postgrad Med 2009;121.33-44.
98. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carro A, Morgia G et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006;70:177-86. (Pubitemid 44000136)
99. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45: 485-93. (Pubitemid 40341327)
100. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006;69:1511-7.
101. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M. Add On Anti-TGF-β Antobody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. J Am Soc nephrol 2003;14:1816-24. (Pubitemid 36750476)
102. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994;46:161-9. (Pubitemid 24210447)
103. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004;15: 2801-15. (Pubitemid 41103389)
104. Weissgarten J, Berman S, Efrati S, Rapaport M, Averbukh Z, Feldman L. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazonetreated pregnant diabetic rats. Nephrol Dial Transplant 2006;21:1198-204.
105. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-55. (Pubitemid 44371272)
106. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-20. (Pubitemid 36919806)
107. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17:1762-4.
108. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE et al. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512-8. (Pubitemid 36173211)
109. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40. (Pubitemid 38250484)
110. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M et al. Glycosaminoglycan therapy prevents TGFbeta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000;11:2324-36.
111. Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009;18:107-11.